论文部分内容阅读
目的 通过负载癌抗原的树突状细胞 (DC)治疗大鼠原发性肝癌 (HCC)模型的实验 ,探讨其临床生物治疗的可行性。方法 用大鼠HCC细胞株CBRH 7919细胞匀浆粗提物 ,刺激Wistar大鼠骨髓衍化的DC ,按不同途径 (静脉、腹腔、癌内注射 )、低中高不同剂量 (10 6、10 7、10 8)静脉注射多次治疗CBRH 7919接种的大鼠HCC模型 ,并设预治疗组、细胞因子加CBRH 7919细胞匀浆粗提物治疗组和生理盐水组作对照 ,用 χ2 检验比较其疗效和生存期。结果 比较各组获得长期生存 (生存大于 10 0d)的大鼠数 ,细胞因子加CBRH 7919细胞匀浆粗提物治疗组、腹腔治疗组及高剂量静脉治疗组与生理盐水组比较无显著意义 (P >0 0 5 ) ;中低剂量静脉治疗组、预治疗组及癌内注射组与生理盐水组比较有显著意义 (P <0 0 5、P <0 0 0 1、P <0 0 0 1和P <0 0 1;预治疗组成癌率与其余各组相比有显著意义 (P <0 0 0 1)。结论 中、低剂量负载癌抗原DC经静脉和癌内多次注射 ,对大鼠HCC有一定的疗效 ,并能有效地抵抗HCC细胞的再接种 ,提示负载癌抗原的DC治疗HCC具有潜在的临床应用前景
Objective To investigate the feasibility of clinical biotherapy in rat primary hepatocellular carcinoma (HCC) models using dendritic cells (DC) loaded with cancer antigens. Methods The crude extracts of rat HCC cell line CBRH 7919 cells were homogenized to stimulate DCs of bone marrow derived Wistar rats. Different doses (venous, intraperitoneal, intratumor injection), low-medium-high doses (10 6, 10 7, 10) were used to stimulate DCs in Wistar rats. 8) Intravenous injection of multiple doses of CBRH 7919-inoculated HCC model in rats, pre-treatment group, cytokine plus CBRH 7919 homogenate crude extract treatment group and normal saline group as control, comparison of efficacy and survival by Chi-square test period. Results The number of rats with long-term survival (>10 days of survival) was compared in each group. Cytokines plus CBRH 7919 homogenate crude extract treatment group, intraperitoneal treatment group and high-dose intravenous treatment group had no significant difference compared with saline group ( P >0 0 5 ) ; The mean dose of intravenous therapy, pretreatment group and intratumoral injection group was significantly higher than that of saline group (P <0 0 5, P <0 0 01, P <0 0 0 1). The pretreatment rate of cancer was significantly higher than that of the other groups (P < 0.01).Conclusion DCs loaded with medium and low doses of cancer antigens were injected intravenously and intratumorly for multiple injections. Mouse HCC has a certain efficacy, and can effectively resist the re-inoculation of HCC cells, suggesting that DCs loaded with cancer antigens have potential clinical applications for HCC treatment